[{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"1511b518-b2d9-44d0-a52a-ddad9c414044","acronym":"CORONADO CLL","url":"https://clinicaltrials.gov/study/NCT05405309","created_at":"2022-06-06T13:56:17.349Z","updated_at":"2024-07-02T16:35:19.578Z","phase":"Phase 1/2","brief_title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05405309 - CORONADO CLL","lead_sponsor":"University of Utah","biomarkers":" TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation","tags":["TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-02-13"}]